Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 11/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 10/20 | 0.51 |
| ▸ | SPR | P35270 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082278 | 0.82 | HSD17B2 (0.48) | HSD17B2HSD17B1SPR | |
| SCHEMBL5761072 | 0.82 | KDM4E (0.56) | ALDH1A1ACHEMEN1KMT2AKDM4E | |
| SCHEMBL27546572 | 0.80 | PYCR1 (0.60) | ALDH1A1ACHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9416589 | 0.80 | ENPP2 (0.54) | HSD17B2HSD17B1ALDH1A1 | |
| SCHEMBL30655576 | 0.78 | SPR (0.57) | SPRALDH1A1KDM4E | |
| SCHEMBL1124591 | 0.78 | SPR (0.57) | SPRALDH1A1KDM4E | |
| SCHEMBL18714775 | 0.77 | ACHE (0.59) | HSD17B2ALDH1A1ACHEMEN1KMT2A | |
| SCHEMBL18586000 | 0.77 | HDAC1 (0.45) | HSD17B2HSD17B1SPR | |
| SCHEMBL30435086 | 0.77 | HSP90AB1 (0.67) | SPRALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL979023 | 0.77 | HSP90AB1 (0.67) | SPRALDH1A1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | HSD17B2 189/4885HSD17B1 177/4885SPR 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.